01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib .
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.